Systemic targeted alpha radiotherapy for cancer

Barry J. Allen

Cancer Pathology & Cell Biology Laboratory, School of Medicine, University of Western Sydney, NSW.

E-mail: bja1940@optusnet.com.au

Abstract

The fundamental principles of internal targeted alpha-therapy for cancer were established many decades ago. The high linear energy transfer (LET) of alpha radiation to the targeted cancer cells causes double strand breaks in DNA. At the same time, the short range radiation spares adjacent normal tissues. This targeted approach complements conventional external beam radiotherapy and chemotherapy. Such therapies fail on several fronts, such as lack of control of some primary cancers (e.g., glioblastoma multiforme) and inhibition of the development of lethal metastatic cancer after successful treatment of the primary cancer.

This review describes the developing role of systemic high LET, internal radiation therapy. Targeted alpha-therapy (TAT) is a rapidly advancing experimental therapy that holds promise to deliver high cytotoxicity to targeted cancer cells. Initially thought to be indicated for leukaemia and micrometastases, there is now evidence that solid tumours can also be regressed.

Alpha therapy may be molecular or physiological in its targeting. Alpha emitting radioisotopes such as $^{212}$Bi, $^{213}$Bi, $^{211}$At and $^{225}$Ac are used to label monoclonal antibodies or proteins that target specific cancer cells. Alternatively, $^{223}$Ra is used for palliative therapy of breast and prostate cancers because of its bone-seeking properties.

Preclinical studies and clinical trials of alpha-therapy are discussed for leukaemia, lymphoma, melanoma, glioblastoma multiforme, bone metastases, ovarian cancer and pancreatic cancers.

Introduction

This review covers the development of internal, high linear energy transfer (LET) radiotherapy from an Australian perspective – more compete bibliographies are available elsewhere (Elgqvist, 2011). Targeted alpha-therapy for cancer has progressed from early in vitro studies, through in vivo experiments to Phase 1 and Phase 2 clinical trials.

Our initial studies related to the production and testing of the alpha-emitting radioisotope $^{149}$Tb. Other research groups used the accelerator produced $^{211}$At. However, the $^{225}$Ac–$^{213}$Bi generator has become the workhorse for the ongoing research.

Targeted Alpha Therapy (TAT) incorporates the essential elements of immunotherapy of cancer: a targeting molecule that fixes to membrane bound molecules on the surface of cancer cells; and a radioisotope label that emits toxic alpha radiation that deposits a large fraction of energy into the targeted cell. There has been a steady rate of in vitro and in vivo alpha publications over the last 25 years, that have clearly demonstrated the potential
superiority of this therapeutic approach. One paper that stands out was the in vivo mouse study (Bloomer, 1984) for mice with peritoneal ascites, which showed that while alpha radiation could lead to regression of the ascites, beta radiation could not. This and other papers were the foundations for our extensive alpha research program, which first began with $^{149}$Tb, the only lanthanide with a significant alpha-decay branching ratio (Allen, 1996). At the same time, Memorial Sloan Kettering Cancer Center was already well down the track with the Ac:Bi generator, which has transformed the practicality of TAT. $^{152}$Tb was later produced at the ISOLDE facility at CERN and $^{149}$Tb at the Tandem accelerator at ANU (Allen 2000) and later in clinical quantities at the 1GeV CERN accelerator (Beyer, 2002). However, $^{149}$Tb failed the practicality test for clinical applications, i.e., it could not be made readily available for clinical use.

The use of gamma-emitting radioisotopes for imaging is well established in Nuclear Medicine. Radioisotopes such as $^{131}$I, $^{123}$I, $^{69}$Ga, $^{203}$Tl and especially $^{99m}$Tc are used to label targeting vectors to allow the pharmacokinetics of radio-conjugates to be determined in human patients via single photon emission computer tomography (SPECT). Positron emission tomography (PET) is developing rapidly as an important diagnostic tool, with $^{18}$F-labelled fluodeoxyglucose (FDG) being the main workhorse with PET imaging machines. While most Nuclear Medicine procedures relate to imaging, a small proportion use $^{131}$I, $^{170}$Lu and $^{90}$Y for therapy of cancer. However, the therapeutic efficacy of beta emitting radioisotopes has been found to be limited and applications are more successful in the palliative setting. In recent years, alpha-emitting radioisotopes have been used in Phase 1 and 2 clinical trials for various cancers. Results generally indicate substantial efficacy well below or at the maximum tolerance dose. It is these studies that are reviewed here.

A number of symposia on alpha-emitting radionuclides in therapy have been held, the most recent being at Berlin (TAT, 2011). The principles and practices of targeted alpha-therapy (TAT) have been previously reported (eg, Allen, (1999), (2006)). The detailed development of the Bismuth alpha-emitting radioisotopes for therapy has been reviewed by Hassfjell (2001). The most recent and complete report of TAT has been published in special issues of Current Pharmaceuticals (Elgqvist (2011)).

**In vitro and in vivo studies**

The Australian program was based on the alpha-emitting radioisotope $^{213}$Bi, which is eluted from the $^{225}$Ac generator (Finn (1997)). The short half-life of $^{213}$Bi, being 46 min, precludes consideration of long biological life times. Monoclonal antibodies have been raised against membrane expressed antigens for many cancers and provide the ability to selectively target those cancers. Stable alpha-conjugates were synthesised in our laboratory by chelating monoclonal antibodies with $^{213}$Bi to form the alpha immuno-conjugates (AIC). These were tested in vitro and in vivo for melanoma (Allen (2001b), Rizvi (2000), leukaemia (Rizvi (2002), colorectal (Rizvi (2001), prostate (Li (2004a, b)), ovarian (Song (2006)) and pancreatic cancers (Qu (2005a, b)).

The short range of alpha-particles, and the short half-life of useful alpha-emitting radioisotopes argue against TAT being at all effective in regressing tumours (Allen (1999a)). Consequently, our studies related to the killing of isolated cancer cells and cell clusters and the inhibition of tumour growth.
To this end we developed the 2-day model, where treatment followed two days post-inoculation of cancer cells.

Mice were then followed until tumours reached ~1 cm$^3$. In all cases, complete inhibition of tumour development was achieved with 300 μCi local sc injection (i.e., in the same location as the cell inoculation). Higher activities were required for systemic (tail vein or intraperitoneal) injection of the AIC. However, efficacy decreases for longer growth times and larger tumours, but can be partially offset by multiple dosing.

Intralesional alpha-therapy was performed on human melanoma xenografts in nude mice (Allen, 2001b) and showed complete tumour regression over 4-8 weeks. Intralesional TAT of melanoma with 300 mCi gave complete regression of melanoma xenografts in nude mice, but was far less successful in breast and prostate tumours. These results paved the way for the intralesional Phase 1 clinical trial (Allen(2006)), wherein the mouse host for the human melanoma was simply exchanged for a human host.

Acute activity tolerances are in the region of 24-36 mCi/kg for systemic (ip) injections. However, long term toxicity (~6 months in mice) in the form of delayed radiation nephrosis, reduces the MTD to ~9 mCi/kg in mice and between 3 and 9 mCi/kg in rabbits.

While kinetics and bio-distributions will depend on the type of vector used, the melanoma trial provided the basic data to determine specific organ doses for comparison with threshold dose levels and the probability of induced secondary cancer. These data are of considerable value in ensuring patient safety in further systemic Phase 1 clinical trials.

### PAI2 – uPAR alpha-therapy

The PAI-2-uPAR targeting system has several important advantages. First, PAI2 is a human protein, rather than a murine antibody, so overcoming problems of immune response. Second, it is a much smaller targeting molecule so can penetrate tissue more efficiently leading to faster targeting, which is important considering the short half-life of the alpha conjugate (46 mins). Finally, pre-clinical studies of over-expression show that uPA is highly expressed in around 75% of pancreatic adenocarcinomas, using immunohistochemical staining, while expression of uPA mRNA in normal pancreas is only 6% of that for pancreatic adenocarcinoma (Nielson (2005); Xue (2008); Qu (2005)). Thus, although there is frequently a high production of uPAR, which predicts poor survival, when there this is countered by a high production of its inhibitor PAI-2 which improved survival results. Therefore the provision of exogenous PAI-2 would not be expected to adversely effect survival.

The human recombinant PAI-2 protein was successfully tested in breast (Allen (2003)), ovarian (Qu (2005), Song (2006, 8), prostate (Li (2002)) and pancreatic (Qu (2005a)) cancers. These conjugates are highly selective of and cytotoxic to targeted cancer cells. In vitro cytotoxicity of alpha-conjugates is very much greater than beta conjugates, non-specific alpha-conjugates and free alpha isotope. The lethal pathway for alpha-therapy is predominantly apoptosis (Li (2004a)).

Preclinical studies of human pancreatic xenografts in nude mice demonstrate complete inhibition of tumour growth at 4 mCi/kg dose at 2 days post-inoculation for local s.c. administration and 9 mCi/kg dose for systemic administration (Qu (2005)). All treated groups showed responses varying
from almost complete inhibition to delayed tumour growth compared with controls. However, the low MW of PAI2 means that renal filtration will lead to delayed radiation nephrosis (Allen (2011a)).

A clinical trial for stage IV pancreatic cancer patients who have either completed or declined standard systemic therapies would soon show efficacy because of the poor prognosis. Any delay in progression of the disease would be of clear benefit to the patient. Systemic targeted alpha-therapy has the potential to regress pancreatic cancers and to eliminate micrometastases. TAT could therefore be indicated for the control of pancreatic cancer after resection of the primary tumour, with potential to control the progression of the disease by regression of micrometastases.

**C595 anti-mucin alpha-therapy**

C595 is an IgG3, murine monoclonal antibody raised against the protein core of human urinary epithelial mucin (MUC1) which is frequently upregulated and abnormally glycosylated in a number of common malignancies, including breast, bladder, colon, ovarian, prostate and gastric cancer. Cancer-associated MUC1 is structurally different to normal MUC1 in that the former has shorter and less dense O-glycan chains, which exposes novel regions of the protein core.

The expression of tumour-associated antigen mucin-1 (MUC-1) on breast, prostate, ovarian and pancreatic cancer cell lines, in cell clusters and animal xenografts was detected by indirect immunostaining. Monoclonal antibodies (MAbs) C595 (test) and A2 (non-specific control) were labelled with $^{213}$Bi using the chelator CHX-A" to form the alpha-immunoconjugate (AIC).

Preclinical results show inhibition of tumour growth and regression of cell clusters. Over 90% of primary prostate, pancreatic and ovarian tumours expressed MUC1 while 95% of normal tissues did not (Qu (2004), Li (2004a), Song (2008b), Allen (2011a)). Further, MUC1 expression was found on the surface of cancer cell lines. The lethal pathway in all *in vitro* studies after TAT was found to be predominantly by apoptosis.

**Clinical Trials**

A great deal of preclinical work paved the way for the advance to clinical trials in recent years. The Sloan Kettering Memorial Cancer Center has led the way, first with the application of $^{213}$Bi immunotherapy and later with $^{225}$Ac. Other laboratories have concentrated on $^{212}$Bi and $^{211}$At. The advantages of the Bi radioisotopes are that they can be generated from long lived parents, $^{225}$Ac with 10 d and Th-$^{228}$ with 1.91 y half-lives, which can be imported from overseas. The Ac-Bi generator has an additional advantage in that it decays in house and does not need long term waste disposal. $^{211}$At, with a 7 hr half-life, needs to be used at or near the production site.

While the half-lives of $^{213}$Bi (46 minutes) and $^{212}$Bi (61 minutes) are rather short, there is sufficient time for synthesis of the alpha-immuno-conjugates, and for vascular distribution throughout the body. However, there is inadequate time for infusion into tumours, which can take 24-48 hours. This is one reason for the development of the $^{225}$Ac alpha-conjugate, as the 10 day half-life allows plenty of time for infusion through the target tumours. On the other hand, the short range of the alpha products requires a high degree of homogeneity if all tumour cells are to be neutralised.
Targeting vectors must be specific for the cancers to be treated. As such, a number of vectors are being used or are to be introduced into the clinic. The following monoclonal antibodies (MAb) are in use: humanised HuM195 targets acute myeloid leukaemia (AML); the murine 9.2.27 targets the MCSP antigen on melanoma cells and GBM cells; the anti-CD20 for lymphoma; MX35 F(ab')2 for ovarian cancer; and the human-mouse chimeric anti-tenascin 81C6 for GBM. In the case of bone cancer, RaCl2 has a natural affinity for bone. Other proposed vectors are PAI2 against uPA, which is widely expressed by many cancers at their most malignant stage and C595 a murine MAb against MUC-1, also of generic nature. The polysaccharide capsule binding MAb 18 B7 is proposed for fungal infection.

Seven clinical trials were reported the Berlin TAT symposium (TAT, 2011). 213Bi was used for studies in acute myelogenous leukaemia (AML), melanoma and lymphoma; 225Ac for AML; 223Ra for bone cancer and 211At for the highest grade brain tumour Glioblastoma Multiforme (GBM) and ovarian cancer. The Phase 1 213Bi trial for acute myeloid leukaemia (AML) has been completed and the current trial is Phase 2 with chemotherapy pre-treatment. The intralesional melanoma trial with 211Bi has also been completed, being followed by a systemic trial with the same alpha conjugate. The following sections review the results of past and current clinical trials, and the objectives of proposed trials.

Current and completed clinical trials are as follows:

- Completed Phase I study for AML (Jurcic (2002))
- Ongoing phase II study for post-chemotherapy of AML (Jurcic (2011))
- Ongoing phase I study with 225Ac (Jurcic (2011))
- Completed Phase 1 trial for intralesional melanoma (Allen, (2006))
- Phase 1 trial of systemic melanoma (Raja (2007); Allen (2008), (2011b)),
- Completed Phase 1 trial of GBM (Zalutsky (2005))
- Completed pilot trial of GBM (Cordier (2010))
- Completed trial of 223Ra for bone metastases (Nilsson (2005)),
- Phase 1 for lymphoma (Miederer (2003)).
- Phase 1 trial in GEP-NET (Kratochwil (2011)).

While solid tumours have never been envisaged as suitable targets for TAT, in contrast with liquid cancers and micrometastases (Allen, 1999a), stage 4 advanced cancer patients are used in Phase 1 trials for toxicity studies.

The intralesional melanoma trial and our current systemic melanoma trial use the 9.2.29 mab to target the melanoma-associated chondroitin sulfate proteoglycan (MCSP) receptor expressed by lesions of more than 90% of melanoma patients. This antigen is the same as the HMWMAA and thought to be identical with the NG2 murine antigen. The antibody is covalently coupled to the cDTPA chelator, and labelled with the 213Bi alpha-emitting radioisotope. The objective of these Phase 1 trials with stage 4 melanoma patients was to determine the safety of the AIC, and so far complications of any type or level have not been observed up to 25 mCi. However, unexpected tumour regressions have been observed at quite low doses, such that a new concept was introduced to explain the clinical responses observed after systemic alpha-therapy, called tumour anti-vascular alpha-therapy (TAVAT) (Allen (2007)).
Leaky neogenic capillaries allow extra-vascular diffusion of the AIC to target antigens on contiguous pericytes and cancer cells. Alpha-emission kills the capillary endothelial cells, shutting down the capillaries with subsequent starvation of the tumour.

**Acute myeloid leukaemia (AML)**

The feasibility, safety and anti-leukaemic activity of the AIC, $^{213}$Bi-CHX-A’-HuM195 was demonstrated in stage 4 subjects with AML (Jurcic (2002)). 18 patients with relapsed and refractory acute myelogenous leukaemia or chronic myelomonocytic leukaemia were treated with 10.36 to 37 MBq/kg of AIC. No significant extramedullary cytotoxicity was observed, but all 17 evaluable subjects developed myelosuppression, with 22 day median recovery time. The AIC localised rapidly within 10 minutes and was retained in areas of leukaemic involvement, including the bone marrow, liver, and spleen.

Absorbed dose ratios for these sites compared to normal tissue were 1,000 times greater than for beta-emitting conjugates. 93% of subjects experienced reductions in circulating blasts, and 78% had reductions in bone marrow blasts. This first alpha-therapy trial in humans showed that the approach was safe, feasible and efficacious.

**Acute myeloid leukaemia Phase 1 and 2**

The Phase 1 study reported in section 3.1 showed that while massive cell kill could be achieved with TAT, the tumour load (~1 kg) was far too high for control to be achieved. A Phase 1/2 trial was implemented that uses partial cyto-reduction with cytarabine (200 mg/m2/day for 5 days) followed by 0.5 to 1.25 mCi/kg of AIC. The maximum tolerance dose (MTD) was ~1 mCi/kg, the dose limiting toxicity being myelosuppression. 6 of 25 subjects (24%) responded at ~1.0 mCi/kg, with 2 complete responses lasting 9 and 12 months, 2 lasting 2 and 5 months and 2 partial responses lasting 4 and 7 months (TAT (2011)).

**Intralesional metastatic melanoma**

The aim was to develop and implement intralesional targeted alpha-therapy (ITAT) for metastatic melanoma, being the first part of a program to establish a new systemic therapy. The benign targeting vector 9.2.27 was labelled with $^{213}$Bi to form the alpha-immunoconjugate $^{213}$Bi-cDTPA-9.2.27 (AIC), which is highly cytotoxic to targeted melanoma cells (Allen (2001)).

The safety and efficacy of intralesional AIC in patients with metastatic skin melanoma was investigated in 16 melanoma patients, all with melanomas that were positive to the monoclonal antibody 9.2.27 (Allen (2005)). AIC doses from 50 to 450 $\mu$Ci were injected into lesions of different sizes, causing massive tumour cell death as observed by the presence of tumour debris. The AIC was very effective in delivering a high dose to the tumour while sparing other tissues. There were no significant changes in blood proteins and electrolytes. There was no evidence of a human-antimouse-antibody reaction. Evidence of significant decline in serum marker melanoma-inhibitory-activity protein (MIA) at two weeks post-TAT was observed.

Intralesional TAT for melanoma in human patients was found to be safe and efficacious to 1350 $\mu$Ci (Allen (2006)). Tumours were resected at 8 weeks post-ITAT, to show massive cell debris in the injected volume, but no effect in untreated tumour or in the antibody only treated tumour in the same patient. Tumour to kidney activity ratios were ~3000. MIA, apoptosis and ki67 proliferation marker tests all indicated that TAT is a promising therapy for the control of
inoperable secondary melanoma or primary ocular melanoma. As such, intralesional TAT could find application for uveal melanoma and brain metastases.

**Bone metastases from breast and prostate cancers – Phase 1 trial**

$^{223}$Ra is a bone-seeking alpha-emitter with potential for palliating breast and prostate cancer metastatic to the bone. A Phase 1 trial has been reported for 15 hormone refractory prostate cancer patients and 10 breast cancer patients, all with metastatic bone disease (Nilsson (2005)). Activities of 50 to 250 kBq/kg were well tolerated; 2/25 subjects experienced grade 3 leucopenia; there was no grade 2+ thrombocytopenia and no dose limiting toxicity. 10/25 subjects suffered diarrhea. Evidence of efficacy was found with substantial reductions in serum alkaline phosphatase (ALP) and improved pain control, but was not dose dependent.

**Bone metastases from prostate cancers – Phase 2 trial**

A randomised, double-blind, placebo controlled, multicentre Phase 2 study investigated the effect of multiple doses of $^{223}$Ra in subject with symptomatic hormone-refractory prostate cancer (Nilsson (2007)). Efficacy endpoints were the reduction in bone-specific ALP concentration and time to occurrence of skeletal-related events (SRE).

Patients due to receive external beam radiotherapy for pain relief were randomly assigned to four-monthly $^{223}$Ra injections or saline injections, in parallel with external beam radiotherapy. Subjects were monitored for survival and long term toxicity out to 24 months. Confirmed PSA response was defined as a 50% reduction from baseline; PSA progression a 25% increase from the nadir and 50% increase for those with a confirmed PSA response. 64 patients were recruited into the trial, 33 being assigned to XBRT plus $^{223}$Ra. Baseline values for both groups were not significantly different, nor were adverse events. However, the $^{223}$Ra group had significant reductions in all five markers, i.e., bone-ALP, total-ALP, PINP, CTX-1 and ICTP. Significant differences were observed with changes in PSA from baseline to four weeks, PSA decreasing by 24% in the $^{223}$Ra group and increasing by 45% in the placebo group. Median time to progression of PSA and survival was 26 weeks and 65 weeks for $^{223}$Ra, compared with eight weeks and 46 weeks for placebo ($P=0.04$ and 0.07).

$^{223}$Ra was fast-tracked by the US Federal Drug Administration (FDA) and is now the first alpha-therapy to be approved for clinical application, specifically for palliation of bone metastases from prostate cancer.

**Glioblastoma Multiforme (GBM)**

The first clinical application of $^{211}$At in humans involved the injection into the resection cavity of escalating doses of $^{211}$At-human antimouse chimeric anti-tenascin MAb 81C6. (Zalutsky, 2005). Injected activities ranged from 2 to 10 mCi, but the MTD was not reached. However, 6 of 17 subjects experienced grade 2 neurotoxicity at 6 weeks, which fully resolved in all but one case. Radionecrosis was not observed. The median delivered dose was 2800 Gy, giving a median survival for GBM subjects (N=14) of 52 weeks and 116 weeks for anaplastic oligodendroglioma (N=3). These results compare favourably with 36 weeks median survival after diagnosis of GBM for standard therapy. Regional administration of $^{211}$At-ch81C6 was found to be feasible, safe and efficacious.
Glioma

Critically located gliomas represent a challenging subgroup of intrinsic brain neoplasms because radical treatment and preservation of neurological function are contrary goals. The successful targeting of gliomas with locally injected $^{90}$Y-DOTAGA-substance P was not indicated for critically located tumours, where the mean beta range of 5 mm may seriously damage adjacent brain areas. $^{213}$Bi emits alpha radiation with a mean range of 81 μm and may have a more favourable toxicity profile. Five patients with critically located gliomas (WHO grades II–IV) were locally injected with $^{213}$Bi-DOTA-substance P in a pilot study (Cordier (2010)). Targeted radio-peptide therapy using $^{213}$Bi-DOTA-substance P was found to be feasible and tolerated without additional neurological deficit. No local or systemic toxicity was observed. $^{213}$Bi-DOTA-substance P showed high retention at the target site. MR imaging was suggestive of radiation induced necrosis and demarcation of the tumours, which was validated by subsequent resection. This study provided proof of concept that targeted local radiotherapy using $^{213}$Bi-DOTA-substance P is feasible and may represent an innovative and effective treatment for critically located gliomas. Primarily non-operable glioma may become resectable with this treatment, possibly improving prognosis.

Lymphoma

Twelve subjects with relapsed or refractory non-Hodgkins lymphoma (NHL) have been treated so far with 28, 33, 39 and 44 MBq/kg of $^{213}$Bi-anti-CD20, without evidence of short term toxicity. Delayed toxicity was experienced by five subjects with myelosuppression and one subject with fever. The dose limiting organ is bone marrow, which received 3.3 to 7.2 mGy/MBq (Schmidt (2004)).

Ovarian Cancer

The $\alpha$-emitter $^{211}$At labelled to a monoclonal antibody has proven safe and effective in treating microscopic ovarian cancer in the abdominal cavity of mice. (Andersson (2009). Women in complete clinical remission after second-line chemotherapy for recurrent ovarian carcinoma were enrolled in a phase I study. The aim was to determine the pharmacokinetics for assessing absorbed dose to normal tissues and investigating toxicity.

Nine patients underwent laparoscopy 2-5 days before the therapy; a peritoneal catheter was inserted, and the abdominal cavity was inspected to exclude the presence of macroscopic tumour growth or major adhesions. $^{211}$At was labelled to MX35 F(ab')$_2$ using the reagent N-succinimidyl-3-(trimethylstannyl)-benzoate. Patients were infused with $^{211}$At-MX35 F(ab')$_2$ (22.4-101 MBq/L) in dialysis solution via the peritoneal catheter. Samples of blood, urine, and peritoneal fluid were collected at 1-48 hours. Hematology, renal and thyroid function were followed for a median of 23 months.

In terms of the initial activity concentration (IC) of the infused solution, the decay-corrected activity concentration decreased with time in the peritoneal fluid to 50% IC at 24 hours, increased in serum to 6% IC at 45 hours, and increased in the thyroid to 127%±63% IC at 20 hours without blocking and less than 20% IC with blocking. No other organ uptakes could be detected. The estimated absorbed dose to the peritoneum was 15.6±1.0 mGy/(MBq/L), to red bone marrow it was 0.14±0.04 mGy/(MBq/L), to the urinary bladder wall it was 0.77 ± 0.19 mGy/(MBq/L), to the unblocked thyroid it
was 24.7 ± 11.1 mGy/(MBq/L), and to the blocked thyroid it was 1.4 ± 1.6 mGy/(MBq/L) (mean ± SD). No adverse effects were observed. Intraperitoneal administration of \(^{211}\text{At-MX35 F(ab')}_2\) could achieve therapeutic absorbed doses in microscopic tumour clusters without significant toxicity.

**Systemic therapy for metastatic melanoma**

The aim of this unique Australian study was to assess toxicity and response of systemic alpha-therapy for metastatic melanoma using the alpha-immunoconjugate \(^{213}\text{Bi-cDTPA-9.2.27 (Raja (2007))}\). Tools used to investigate the responses were physical examination; imaging of tumours; pathology comparisons over 12 weeks; glomelular filtration rate (GFR) for renal activity; computed tomography (CT) for tumour responses and changes in tumour marker over 8 weeks. Responses were based on RECIST criteria.

40 patients with stage IV melanoma/ in-transit metastasis were treated with activities of 55-947 MBq. Using RECIST criteria 50% of subjects experienced stable disease and 12% showed partial response. One patient showed near complete response after a 5 mCi intravenous injection of the AIC (20/21 lesions completely disappeared) and was retreated at 12 months because of an excellent response to the initial treatment. Another patient showed response in his tumour on mandible and reduction in lung lesions. 30% of patients experienced progressive disease over 8 weeks, and all subjects eventually progressed and succumbed to the disease.

The tumour marker melanoma inhibitory activity protein (MIA) reduced over 8 weeks in most patients. However, there was a disparity of dose with responders. Toxicity at any level was not observed over the range of administered activities.

The observation of responses without any toxicity indicates that targeted alpha-therapy has the potential to be a safe and effective therapeutic approach for metastatic melanoma. The observation of efficacy at quite low doses showed that this trial, while adequate as a Phase 1, was inadequate to investigate the underlying factors that were contributing to the unexpected efficacy. As such, the trial was terminated in June 2007 without reaching the MTD and a new trial was designed to provide more detailed information.

**Improvements to the trial**

The earlier trial used the cDTPA chelator to link the antibody and radioisotope, as this was the only commercially available chelator at that time. As delayed radiation nephrosis is the main concern, CHX-“A”, being more stable, is expected to reduce the renal uptake of free \(^{213}\text{Bi} and so increase the maximum tolerance dose for the kidneys. Further, commercial production of CHX-“A” is now available (Macrocycles, USA).

The monoclonal antibody 9.2.27 targets the MCSP antigen and if expression is low, antigens can be more readily saturated and blocked by unlabelled antibody, thus limiting tumour regression. One way around this problem is to increase the specific activity (SA) of the AIC. The AIC is usually prepared by minimizing the free radio-isotope in the labeling process. However, our objective is to minimize the unlabelled antibody fraction. This then leads to a higher SA, less blocking of target antigens, and more effective therapy. Further, the higher specific activity will reduce the amount of antibody injected, even at
higher activities, therefore reducing the HAMA effect. Dose limiting toxicity will be defined in terms of renal function; GFR Grade 1 (normalized for age) or Grade 2 serum creatinine. GFR will be measured at 0, 26, 52 and 78 weeks. If there is >25% decline GFR will be repeated in one month for verification. Serum creatinine will be measured at each visit.

A single administration of AIC was given in the first trial, (if needed 2-3 injections on the same day to achieve the required injected activity). With the higher activities, a fractionated dose regime will be more practical, and may give improved efficacy as tumours capillaries may be damaged, resulting in increased permeability for the AIC. Daily fractionation over 4-5 days would not be of concern for immune response (HAMA) as the time period is too short for the generation of an immune response (7-14 days).

Blocks of previous biopsies will be obtained with the consent of the patient to assess the expression of the targeted antigen MCSP. Tumour biopsy may be taken to observe the effect of the therapy. Biological dosimetry will be obtained by observation of radiation damage to peripheral blood lymphocytes (Song (2007a)). Radiation causes the formation of micronuclei in lymphocytes, which can be counted before and after treatment with blood samples.

Unfortunately, this trial was denied site approval at St George Hospital for fiscal reasons and never proceeded.

**Discussion**

Alpha therapy for acute myeloid leukaemia was very effective in reducing the cancer cell load. When used with prior chemotherapy at the maximum tolerance dose, some important complete and partial responses are observed.

Patient data for Non-Hodgekins Lymphoma are not as encouraging and its not yet clear if responses will be observed at the maximum tolerance dose.

In the case of intralesional TAT, quite low injected activities (<0.5 mCi) can bring about tumour regression. Even with systemic therapy, and contrary to expectations, melanomas have been completely regressed without recurrence with systemic administration of <10 mCi of AIC. There is no evidence of any adverse events up to 25 mCi. The ability to regress solid tumours was unexpected, and is explained by tumour anti-vascular alpha-therapy (TAVAT), as hypothesised by Allen et al (2007). The diffusion of AIC by leaky tumour capillaries into the peri-capillary space allows the antigens of pericytes and contiguous cancer cells to be targeted, from which alpha rays can kill endothelial cells, leading to closure of the capillaries. If enough capillaries are closed down, then the tumour may regress. The variable tumour capillary permeability is expected to be the major determining factor in TAVAT.

Monte Carlo calculations of the microdosimetry (Huang (2011) show that TAVAT is theoretically possible in terms of $^{213}$Bi blood concentrations, endovascular diffusion times and the probability of alpha hits and energy deposition to the capillary endothelial cell nucleus.

Intra-cavity administration of the AIC for GBM shows improved survival of 52 weeks without serious adverse events. This approach is promising for improving prognosis of this fatal disease.
Palliative therapy with $^{223}$Ra appears promising for breast and prostate cancer metastatic to the bone. When used as therapy adjunctive to external beam radiotherapy, marked reductions in PSA are seen for prostate cancer.

Intraperitoneal administration of the AIC for ovarian cancer may also be effective, and so far has not induced any adverse events.

A number of preclinical studies should lead to new clinical trials. Among these are the use of PAI2 as a targeting vector for pancreatic cancer. Being a small molecule (MW=47 kD), alpha-PAI2 may more easily diffuse through tumour capillary fenestrations to target cancer cells, and set up a TAVAT effect. On the down side is the higher renal uptake arising from the lower MW. PAI2 targets UPA, a generic receptor expressed by many cancers. Also generic in nature is the MUC-1 receptor, targeted by the MAb c595.

Targeted alpha-therapy could also have application for the control of microbial disease and for AIDS. The potential role of alpha-therapy has been explored for fungal disease, the human pathogens Cryptococcus neoformans and Histoplasma capsulatum, and pneumococcal infection and viral disease (Dadachova, 2006).

Of some concern is the impact of second cancers, arising from point mutations from stochastic radiation damage to chromosomes and incorrect radiation damage repair. The high radiation weighting factor for alpha-particles ($R_w=20$) could limit the application of TAT to end stage cancers. The mutagenic potential of $^{213}$Bi conjugated to a human melanoma antigen-specific antibody (9.2.27) was examined using an in vivo transgenic mouse model containing multiple copies of a lacZ target gene in every cell, allowing the quantification and comparison of mutagenesis in different organs (Allen (2009)). The mutant frequency and mutant spectra were analysed for the brain, spleen and kidneys. The brain and spleen did not show significant increases in induced mutation frequencies compared to spontaneous background levels or changes in mutant spectra, these results being independent of the status of the tumour suppressor gene p53. However, elevated mutation frequencies and persistent size change mutations were observed in the kidneys, but were not significant (P=0.05). The effect of p53 status was also evident, as p53 heterozygotes displayed higher mutation frequencies than their wild-type counterparts, suggesting a reduction in the p53 gene may lead to an increased susceptibility to mutagenesis. These effects were time dependent and levels returned to those of the controls at four weeks post-irradiation, albeit with a predominant residue of size mutations. However, these mutations were observed at activities very much higher than those expected for the therapy of human patients. As such, the induction of secondary cancer with the $^{213}$Bi-DTPA-9.2.27 alpha immunoconjugate is not expected to be a significant problem in the clinic.

The objectives in the application of targeted alpha-therapy (TAT) for cancer therapy relate to the elimination of isolated cancer cells, cell clusters and tumours. Requirements for isolated cancer cells are good cellular targeting, high specific activity and very short range to spare normal tissue. The regression of cell clusters in the peri-vascular space requires high capillary permeability and short range cross fire whereas for developed tumours, good bio-availability and anti-capillary activity are essential (Allen (2011c)).
Of the current sources of alpha radiation, the Ac:Bi generator is the most practical, bringing therapy to Nuclear Medicine with the same practicality as the Mo:Tc generator has for imaging.

Conclusions

Alpha therapy is still a work in progress, but great gains are being made in translating from preclinical studies to clinical trials. Ideally suited to leukaemia, alpha-therapy is demonstrating efficacy, but at the maximum tolerance dose level. Glioblastoma multiforme results from intra-cavity administration are very promising, with 52 week median survival. However, the promise of targeted alpha-therapy is greatly extended by the development of tumour antivascular alpha-therapy for solid tumours. Metastatic melanoma results show surprising tumour regressions at doses very much below the maximum tolerance dose and if further research is successful, could change the prognosis for end-stage cancers. More studies are needed in the fields of dose normalization, real time microdosimetry and biological dosimetry for deterministic and stochastic effects.

Acknowledgements

The TAT project needs the skills of many colleagues; Drs S. Rizvi in radiochemistry, C. Raja in clinical trials, Y Li in immunology and past and present PhD students S. Rizvi, C.F. Qu, E.Y. Song and C.Y. Huang. Clinical collaborators were Professors P. Graham, J. Kearsley at St George Hospital, R. Smith at Royal North Shore Hospital and J. Thompson at Royal Prince Alfred Hospital. Our project depends heavily on support from Drs A. Morgenstern and C. Apostolidis at the Institute for Transuranium Elements (ITU), Germany.

These acknowledgements would not be complete without noting the extensive grant support for our targeted alpha-therapy program by the US Department of Defence, which has substituted for the lack of support from Australian funding agencies.

References


Barry Allen

(Manuscript received 21 October 2011; accepted 5 March 2012.)

**Professor Barry Allen** is a biomedical physicist previously at the St George Cancer Care Centre and Clinical School, St George Hospital, Sydney. Previously, he was a Chief Research Scientist at the Australian National Nuclear Research and Development Organisation (ANSTO). During this time he published widely in keV neutron capture reactions, investigating neutron capture mechanisms and their relationship to stellar nucleosynthesis and cross-section data for fast reactors.